Insulet Corporation (PODD)

Currency in USD
152.48
+3.19(+2.14%)
Closed·
152.70+0.22(+0.14%)
·
PODD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
145.31153.79
52 wk Range
126.40354.88
Key Statistics
Prev. Close
149.29
Open
150.47
Day's Range
145.31-153.79
52 wk Range
126.4-354.88
Volume
1.59M
Average Vol. (3m)
1.57M
1-Year Change
-54.1689%
Book Value / Share
22.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
178.57
Upside
+17.11%
Members' Sentiments
Bearish
Bullish
ProTips
18 analysts have revised their earnings downwards for the upcoming period

Insulet Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

15 Buy
11 Hold
0 Sell
Ratings:
26 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 178.57
(+17.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Hold160.00+4.93%153.00MaintainNov 09, 2026
Truist Securities
Hold160.00+4.93%153.00MaintainNov 06, 2026
Barclays
Hold165.00+8.21%150.00MaintainNov 06, 2026
RBC Capital
Buy180.00+18.05%160.00MaintainNov 05, 2026
Bernstein SocGen Group
Buy200.00+31.16%175.00MaintainNov 05, 2026

Insulet Corporation SWOT Analysis


Competitive Edge
Insulet's tubeless patch pump technology differentiates it in diabetes care, showing strong T2II patient preferences while navigating competition from alternative treatments
Analyst Outlook
Price targets range from $301 to $370, with an average around $326, reflecting confidence in Omnipod's technology advantages despite execution uncertainties
Market Paradox
Despite robust Q3 earnings and overwhelming analyst support with 90% Buy ratings, the stock declined amid GLP-1 drug pricing concerns and valuation questions
Growth Ambitions
Management unveiled a bold 20% three-year growth plan, surpassing Street estimates by 200-300 basis points through T2II market penetration and international expansion
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q3/2026

  • Insulet reported Q3 2026 adjusted EPS of $1.99, beating estimates by 25%, with revenue up 19.2% to $842M, exceeding forecasts by 1.08%.
  • Gross margin expanded to 74.2% and operating margin rose to 22%, driven by productivity gains and scale benefits across U.S. and international markets.
  • Company raised 2026 revenue growth outlook to 21-22% and approved $1B share buyback increase, planning $400M in Q4 repurchases.
  • Management signaled 2027 growth will slow below mid-teens target due to tougher comparisons, larger revenue base, and expected competition pressures.
  • CEO McEvoy cited timing of product launches including Omnipod 6 as key factor, while maintaining long-term confidence in automated insulin delivery market.
Last Updated: 11/04/2026, 09:56 AM
Read Full Transcript
Insulet investor slides for Q3/2026
Insulet Q3 2026 slides
Last Update: Nov 04, 2026
See full investor slides

Earnings

Latest Release
Nov 04, 2026
EPS / Forecast
1.99 / 1.59
Revenue / Forecast
842M / 832.98M
EPS Revisions
Last 90 days

PODD Income Statement

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
24.7x13.6x−0.2x
PEG Ratio
0.310.160.00
Price / Book
6.7x7.8x2.6x
Price / LTM Sales
3.3x3.9x2.8x
Upside (Analyst Target)
17.1%60.8%65.0%
Fair Value Upside
Unlock−4.7%9.6%Unlock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
35.17M50.70%5.36B
Other Institutional Investors
32.45M46.77%4.95B
Public Companies & Retail Investors
1.75M2.52%266.97M
Total
69.37M100.00%10.58B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.69%5,337,778813,904
Vanguard Capital Management, LLC7.10%4,923,350750,712

People Also Watch

720.19
FICO
+0.39%
44.34
BSX
+0.32%
83.82
ZTS
+1.04%
409.10
APP
+3.92%
315.43
AXON
+2.71%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 152.48 USD.

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 10.36B USD.

What Is Insulet's Earnings Per Share (TTM)?

The Insulet EPS (TTM) is 6.15.

When Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Feb 25, 2027.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times.

How Many Employees Does Insulet Have?

Insulet has 5400 employees.

What is the current trading status of Insulet (PODD)?

As of Nov 14, 2026, Insulet (PODD) is trading at a price of 152.48 USD, with a previous close of 149.29 USD. The stock has fluctuated within a day range of 145.31 USD to 153.79 USD, while its 52-week range spans from 126.40 USD to 354.88 USD.

What Is Insulet (PODD) Price Target According to Analysts?

The average 12-month price target for Insulet is 178.57 USD, with a high estimate of 200 USD and a low estimate of 160 USD. 15 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +17.11% Upside potential.

What Is the PODD Premarket Price?

PODD's last pre-market stock price is 150.43 USD. The pre-market share volume is 6,810.00, and the stock has decreased by 1.14, or 0.76%.

What Is the PODD After Hours Price?

PODD's last after hours stock price is 152.70 USD, the stock has decreased by 0.22, or 0.14%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.